An intensive care nurse treating a newborn with RSV in Germany. Sanofi’s new antibody is designed to protect all infants from the common and occasionally severe infection. (Marijan Murat/picture-alliance/dpa/AP Images)
With new RSV antibody, Sanofi looks to avoid a repeat of a 20-year-old pricing controversy
Twenty-four years ago, the FDA approved a drug as controversial as it was innovative.
Known as Synagis, it was OK’d for protecting certain infants against respiratory syncytial virus, or RSV, the leading cause of infant hospitalization in the US and Europe. It was the first antibody approved for an infectious disease, a forerunner of the antibody treatments deployed during the pandemic to treat or protect people from Covid-19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
